Efficacy and Safety of Combination Therapy with Low-dose Pravastatin and Fenofibrate for Combined Hyperlipidemia / 中华高血压杂志

ABSTRACT

Objective The aim of this study was to evaluate the efficacy and safety of combination therapy with low-dose pravastatin and fenofibrate in patients with combined hyperlipidemia. Methods One hundred eighty nine patients with combined hyperlipidemia were randomly assigned to receive 10 mg pravastatin (n=64) or 200 mg fenofibrate (n=63), or a combination of 10 mg pravastatin and 200 mg fenofibrate (n=62) for 12 weeks. The patients in the monotherapy groups (n=35) whose lipid levels were not controlled after 12 weeks were randomly assigned to receive 20 mg pravastatin, or 200 mg fenofibrate, or a combination of 10 mg pravastatin and 200 mg fenofibrate for another 12 weeks. Lipid levels and adverse effects were assessed. Results After 12 weeks treatments, serum TC, LDL-C and TG levels were reduced and HDL-C was increased more significantly in combination therapy group, compared with 2 monotherapy groups (all P